BACKGROUND: Little is known about how drug presentation influences medication adherence. OBJECTIVE: To examine the effect of an educational program aimed at increasing expectations of treatment benefit on medication adherence. METHODS: Data are analyzed from 99 participants who underwent electronic drug monitoring during the Trial of Asthma Patient Education, a randomized, placebo-controlled, multicenter trial. Participants with suboptimally controlled asthma were randomized to placebo or montelukast in conjunction with a presentation mode that was either neutral or designed to increase outcome expectancy. Adherence was monitored electronically over 4 weeks and was defined as ≥ 80% use of prescribed doses. Outcome expectancy, peak expiratory flow, prebronchodilator FEV₁, asthma control (Juniper asthma control questionnaire), and asthma-related quality of life were assessed at baseline and at the 4-week follow-up. RESULTS:Average electronic medication adherence was 69.9%. There was a significant interaction between presentation mode and drug assignment, with participants in the enhanced/montelukast group having a higher change in outcome expectancy (Δ 2.1 points; P < .001) and better medication adherence (odds ratio, 4.0; 95% CI, 1.1-14.3) compared with those in the neutral/placebo group. There was no difference in asthma symptoms, quality of life, or clinical outcomes on the basis of presentation mode. Rather, increased outcome expectancy was associated with modest improvements in asthma symptoms after adjusting for presentation mode, drug assignment, and medication adherence. CONCLUSION: The use of an enhanced presentation aimed at increasing outcome expectancy may lead to improved medication adherence.
RCT Entities:
BACKGROUND: Little is known about how drug presentation influences medication adherence. OBJECTIVE: To examine the effect of an educational program aimed at increasing expectations of treatment benefit on medication adherence. METHODS: Data are analyzed from 99 participants who underwent electronic drug monitoring during the Trial of AsthmaPatient Education, a randomized, placebo-controlled, multicenter trial. Participants with suboptimally controlled asthma were randomized to placebo or montelukast in conjunction with a presentation mode that was either neutral or designed to increase outcome expectancy. Adherence was monitored electronically over 4 weeks and was defined as ≥ 80% use of prescribed doses. Outcome expectancy, peak expiratory flow, prebronchodilator FEV₁, asthma control (Juniper asthma control questionnaire), and asthma-related quality of life were assessed at baseline and at the 4-week follow-up. RESULTS: Average electronic medication adherence was 69.9%. There was a significant interaction between presentation mode and drug assignment, with participants in the enhanced/montelukast group having a higher change in outcome expectancy (Δ 2.1 points; P < .001) and better medication adherence (odds ratio, 4.0; 95% CI, 1.1-14.3) compared with those in the neutral/placebo group. There was no difference in asthma symptoms, quality of life, or clinical outcomes on the basis of presentation mode. Rather, increased outcome expectancy was associated with modest improvements in asthma symptoms after adjusting for presentation mode, drug assignment, and medication adherence. CONCLUSION: The use of an enhanced presentation aimed at increasing outcome expectancy may lead to improved medication adherence.
Authors: Andrea J Apter; Ray C Boston; Maureen George; A Lorraine Norfleet; Thomas Tenhave; James C Coyne; Kathleen Birck; Susan T Reisine; Andrew J Cucchiara; Harold I Feldman Journal: J Allergy Clin Immunol Date: 2003-06 Impact factor: 10.793
Authors: J Y Lee; J W Kusek; P G Greene; S Bernhard; K Norris; D Smith; B Wilkening; J T Wright Journal: Am J Hypertens Date: 1996-08 Impact factor: 2.689
Authors: L Keoki Williams; Manel Pladevall; Hugo Xi; Edward L Peterson; Christine Joseph; Jennifer Elston Lafata; Dennis R Ownby; Christine C Johnson Journal: J Allergy Clin Immunol Date: 2004-12 Impact factor: 10.793
Authors: Sandra R Wilson; Peg Strub; A Sonia Buist; Sarah B Knowles; Philip W Lavori; Jodi Lapidus; William M Vollmer Journal: Am J Respir Crit Care Med Date: 2009-12-17 Impact factor: 21.405
Authors: Michiko Otsuki; Michelle N Eakin; Cynthia S Rand; Arlene M Butz; Van Doren Hsu; Ilene H Zuckerman; Jean Ogborn; Andrew Bilderback; Kristin A Riekert Journal: Pediatrics Date: 2009-12 Impact factor: 7.124
Authors: L Keoki Williams; Edward L Peterson; Karen Wells; Brian K Ahmedani; Rajesh Kumar; Esteban G Burchard; Vimal K Chowdhry; David Favro; David E Lanfear; Manel Pladevall Journal: J Allergy Clin Immunol Date: 2011-10-21 Impact factor: 10.793
Authors: Dana Tiggelman; Monique O M van de Ven; Onno C P van Schayck; Rutger C M E Engels Journal: Qual Life Res Date: 2015-02-26 Impact factor: 4.147
Authors: Juan C Celedón; Esteban G Burchard; Dean Schraufnagel; Carlos Castillo-Salgado; Marc Schenker; John Balmes; Enid Neptune; Kristin J Cummings; Fernando Holguin; Kristin A Riekert; Juan P Wisnivesky; Joe G N Garcia; Jesse Roman; Rick Kittles; Victor E Ortega; Susan Redline; Rasika Mathias; Al Thomas; Jonathan Samet; Jean G Ford Journal: Ann Am Thorac Soc Date: 2017-05
Authors: Amy Chan; Anna De Simoni; Vari Wileman; Lois Holliday; Chris J Newby; Claudia Chisari; Sana Ali; Natalee Zhu; Prathima Padakanti; Vasita Pinprachanan; Victoria Ting; Chris J Griffiths Journal: Cochrane Database Syst Rev Date: 2022-06-13